At 7.4% CAGR, the Asia Pacific Acute Pancreatitis Market is projected to be worth US$ 1,076.06 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific acute pancreatitis market was valued at US$ 607.35 million in 2022 and is expected to reach US$ 1,076.06 million by 2030, registering a CAGR of 7.4% from 2022 to 2030. Rise in pancreatic cancer cases due to acute pancreatitis and rising incidence of diabetes following acute pancreatitis are among the critical factors attributed to the Asia Pacific acute pancreatitis market expansion.             

The pancreas produces insulin, a hormone that regulates blood sugar levels. Pancreatitis can harm insulin-producing cells of pancreas, which causes diabetes in patients suffering from acute pancreatitis. People suffering from acute pancreatitis are at a twofold greater risk of diabetes as compared to the general population. The World Health Organization (WHO) has classified the development of diabetes after acute pancreatitis as exocrine pancreatic diabetes (pancreatogenic diabetes). Pancreatogenic diabetes is increasingly being linked to exocrine disorders of the pancreas. Diabetes sequelae are observed across the spectrum of severity in acute pancreatitis and can accompany other clinical complications. A Chinese research study suggests that hypertriglyceridemia (HTG) has outpaced alcohol to become the second leading cause of acute pancreatitis. Approximately 29% of patients experience repeated episodes that result in recurrent acute pancreatitis (RAP) and 44.6% of these patients had HTG as an etiological condition. In an article published in Biomed Central in June 2023, HTG has been stated as a significant independent risk factor for the severity and recurrence of acute pancreatitis. Thus, the increasing incidence of diabetes in patients suffering or recovering from acute pancreatitis contributes to the growth of the Asia Pacific acute pancreatitis market.

On the contrary, side effects of pancreatitis and pancreatic cancer treatments hampers on the growth of Asia Pacific acute pancreatitis market. 

Based on offerings, the Asia Pacific acute pancreatitis market is categorized into medications, diagnosis, and others. The diagnosis segment held 56.2% market share in 2022, amassing US$ 341.35 million. It is projected to garner US$ 602.21 million by 2030 to expand at 7.4% CAGR during 2022–2030.

Based on causes, the Asia Pacific acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held 48.2% share of Asia Pacific acute pancreatitis market in 2022, amassing US$ 292.46  million. It is projected to garner US$ 532.73 million by 2030 to expand at 7.8% CAGR during 2022–2030.

Based on end user, the Asia Pacific acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held 74.5% share of Asia Pacific acute pancreatitis market in 2022, amassing US$ 484.99 million. It is projected to garner US$ 796.70 million by 2030 to expand at 7.3% CAGR during 2022–2030.

Based on country, the Asia Pacific acute pancreatitis market has been categorized into the China, India, South Korea, Japan, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.3% share of Asia Pacific acute pancreatitis market in 2022. It was assessed at US$ 177.65 million in 2022 and is likely to hit US$ 310.44 million by 2030, exhibiting a CAGR of 7.2% during 2022–2030.            

Key players operating in the Asia Pacific acute pancreatitis market are Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare, among others.

• In Oct 2021, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, introduced the V8, a new high-end ultrasound system that provides enhanced image quality, usability and convenience for all medical professionals.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com